Drug intelligence / Profile preview

Cobaltous chloride + technetium tc-99m exametazime

Development stage: Approved
Lead developer: GE Healthcare
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This drug is a combination used in nuclear medicine for diagnostic imaging. Technetium Tc-99m exametazime is a radiopharmaceutical that, when combined with cobaltous chloride as a stabilizer, forms a complex used for imaging cerebral perfusion and other diagnostic purposes. The technetium Tc-99m component emits gamma rays for imaging with devices like SPECT cameras, providing valuable insights into brain function and perfusion. It is particularly useful in stroke diagnosis and other neurological conditions.

Brand names: Ceretec
Other names: technetium tc 99m exametazime and cobaltous chloride kit

Beyond the preview

Go deeper on Cobaltous chloride + technetium tc-99m exametazime.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cobaltous chloride + technetium tc-99m exametazime.

Explore the full profile